How Infectious Disease Experts Are Coping With the COVID-19 Pandemic (On-Demand Webinar)

Assessment of Needs

With the ongoing demands of responding to the COVID-19 pandemic, clinicians and other frontline health care professionals are particularly vulnerable to burnout, stress, and other negative mental health effects. In this panel webinar, the IAS–USA Board of Directors will share personal stories of their experiences from early on during the pandemic to now, including how they have been dealing with the surge of COVID-19 cases and coping with stress. The panel will be moderated by Nadine J. Kaslow, PhD, Professor of Psychiatry and Behavioral Sciences at Emory University.

Learning Objectives

On completion of this webinar, learners will be able to:

• Describe approaches that thought leaders in the field have used to manage stress and maintain mental and overall health and use those strategies to keep up their own health and the health of staff and colleagues
• Describe the magnitude of the response to the COVID-19 pandemic and its effects upon everyone in the health care system

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, pharmacists, and other health professionals.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Dr Currier has served on the advisory board for Merck & Co, Inc. (Updated 05/15/19)

Dr del Rio has no relevant financial affiliations to disclose. (Updated 06/20/20)

Dr Gulick has no relevant financial affiliations to disclose. (Updated 09/10/20)

Dr Kaslow has no relevant financial affiliations to disclose. (Updated 02/11/21)

Dr Marrazzo has received research grants from Merck & Co, Inc, and Cepheid; served as an advisor to Gilead Sciences, Inc, and BioFire Diagnostics, and served on a data safety monitoring board for Gilead Sciences, Inc. (Updated 09/02/19)

Dr Richman has been a consultant to Antiva Biosciences, Gilead Sciences, Inc, and Viriome, Inc. (Updated 12/10/20)

Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, and ViiV Healthcare. (Updated 06/20/20)

Dr Schooley has served as a consultant to CytoDyn and has receives royalties from Antiva Biosciences and CytoDyn. He serves on the board for Gilead Sciences, Inc., with payment remitted to his institution. He serves on the data and safety monitoring boards for Gilead Sciences, Inc., and VIR with payment remitted to his institution. (Updated 02/20/20)

Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc. (Updated 06/20/20)

Planner/Reviewer

Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 02/23/21)
Planner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 02/23/21)

All relevant financial relationships have been mitigated.